Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.

Wellcome Trust supports the development of sirolimus in beta - thalassemia, a collaborative project between Rare Partners and Ferrara University

News - read more

Sirolimus has been granted Orphan Drug Designation for the treatment of sickle cell disease also in USA

RP announcement - read more

Orphan Drug Designation to sirolimus in Sickle Cell Disease

RP announcement - read more
Syndicate content